Streetbeat News

Price Targets

ROIV

Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Roivant Sciences (NASDAQ:ROIV) and maintained a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:09 pm

OI

Truist Securities analyst Michael Roxland has reiterated a 'Buy' rating on O-I Glass (NYSE:OI) and maintained a price target of $31.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:08 pm

LUV

Bernstein analyst David Vernon has maintained a 'Market Perform' rating on Southwest Airlines (NYSE:LUV) but lowered the price target from $32 to $28.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:07 pm

IMVT

Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Immunovant (NASDAQ:IMVT) and maintained a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:06 pm

AAL

Bernstein analyst David Vernon has maintained an 'Outperform' rating on American Airlines Group (NASDAQ:AAL) but lowered the price target from $26 to $23.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:06 pm

XGN

Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Exagen (NASDAQ:XGN) and maintained a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:02 pm

SMTI

Cantor Fitzgerald analyst Brandon Folkes has reiterated an Overweight rating on Sanara MedTech (NASDAQ:SMTI) and maintained a $59 price target.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:01 pm

WDAY

Over the past 3 months, 30 analysts have published their opinion on Workday (NASDAQ:WDAY) stock. The company has an average price target of $259.77, which has increased by 7.49% from the previous average price target of $241.66. The majority of the analysts are somewhat bullish on the stock.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 4:00 pm

SIBN

Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on SI-BONE (NASDAQ:SIBN) and maintained a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 3:59 pm

RCEL

Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on AVITA Medical (NASDAQ:RCEL) and maintained a $26 price target.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 3:52 pm